Sarepta Therapeutics Inc
SRPT - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.97B
Close$
$153.22
706.9% upside
Current Fair Value
706.9% upsideUndervalued by 706.9% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $1.97 Billion |
|---|---|
| Enterprise Value | $2.55 Billion |
| Earnings per Share | $-7.13 |
| Beta | 0.21 |
| Outstanding Shares | 105,431,000 |
Return
| Return on Equity | -17.42% |
|---|---|
| Return on Assets | -8.35% |
| Return on Invested Capital | -8.04% |
Valuation & Multiples
| P/E Ratio | -12.93 |
|---|---|
| PEG | 12.62 |
| Price to Sales | 1.06 |
| Price to Book Ratio | 1.36 |
| Enterprise Value to Revenue | 1.29 |
| Enterprise Value to EBIT | -11.81 |
| Enterprise Value to Net Income | -10 |
| Total Debt to Enterprise | 0.45 |
| Debt to Equity | 0.76 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 4, 2026
EPS Estimate
$0.07
Consensus analyst estimateRevenue Estimate
$352.20 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 133.06% |
|---|---|
| Total Calls | 1,465▼ 99.94% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.05%▼ 101.97% |
|---|---|
| Total Invested | $20.09M▼ 98.97% |
| Investors Holding | 68▼ 281.00% |
About Sarepta Therapeutics Inc
835 employees
CEO: Douglas Ingram
Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the...